Deerfield Mgmt L.P.
CIK 1010823 · last filed 2024-10-24
Deerfield Mgmt L.P. is a corporate insider who has filed 54 SEC Form 4 insider transactions across 32 companies since 2007. The most recent filing shows the insider sold $1.56B of NUVL on Oct 24, 2024. Across all open-market trades the lifetime net is −$1.01B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $252.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$252.41M
Companies
32
Total Filings
54
Lifetime Open-Market Net
-$1.01B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NUVL | Director | 650,000 | $123.96 | $80.57M | -$1.39B | 2 | 2024-10-24 |
| Oncorus, Inc. (ONCR) Delisted | 10%+ Owner | 1,351,374 | $0.12 | $162.9K | -$301.0K | 1 | 2022-12-21 |
| XLO | 10%+ Owner | 81,712 | $9.15 | $747.7K | $62.00M | 1 | 2021-10-28 |
| DA32 Life Science Tech Acquisition Corp. (DALS) Delisted | Director | 1,600,000 | $10.32 | $16.51M | $64.00M | 1 | 2021-08-03 |
| CareMax, Inc. (CMAXW) Delisted | Director | 3,768,750 | $0.01 | $36.2K | $0 | 1 | 2021-06-10 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | 10%+ Owner | 2,382,033 | $52.95 | $126.13M | $45.22M | 1 | 2021-02-09 |
| ANNX | 10%+ Owner | 808,914 | $4.97 | $4.02M | $71.40M | 1 | 2020-07-28 |
| CareMax, Inc. (DFHTU) Delisted | Director | 3,360,000 | $15.65 | $52.58M | $0 | 1 | 2020-07-22 |
| SDGR | 10%+ Owner | 250,000 | $15.29 | $3.82M | $25.50M | 1 | 2020-02-10 |
| XERS | 10%+ Owner | 857,821 | $8.24 | $7.07M | -$655.5K | 1 | 2019-02-12 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | 10%+ Owner | 835,843 | $33.99 | $28.41M | $12.00M | 1 | 2018-07-23 |
| Keenova Therapeutics plc (MNK) Delisted | 10%+ Owner | 8,308,455 | $0.34 | $2.83M | -$16.76M | 1 | 2018-05-10 |
| EHTH | 10%+ Owner | 428,367 | $1.36 | $582.6K | $27.88M | 5 | 2017-04-27 |
| CAS MEDICAL SYSTEMS INC (CASM) Delisted | 10%+ Owner | 3,128,087 | — | — | -$1.25M | 1 | 2017-01-23 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | 10%+ Owner | 95,984 | — | — | -$26.66M | 1 | 2016-08-01 |
| BOLD | 10%+ Owner | 889,230 | $2.47 | $2.20M | $36.00M | 1 | 2016-07-25 |
| XENOPORT INC (XNPT) Delisted | 10%+ Owner | 6,667,391 | — | — | $5.67M | 1 | 2016-01-22 |
| VNDA | 10%+ Owner | 2,152,952 | $5.16 | $11.11M | $600.9K | 1 | 2015-12-18 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 300,177 | $5.54 | $1.66M | $3.20M | 2 | 2015-11-10 |
| ANTARES PHARMA, INC. (ATRS) Delisted | 10%+ Owner | 6,807,533 | $5.59 | $38.05M | -$19.69M | 1 | 2015-09-30 |
| AXGN | 10%+ Owner | 3,381,439 | $41.15 | $139.15M | -$7.59M | 1 | 2015-09-22 |
| SteadyMed Ltd. (STDY) Delisted | 10%+ Owner | 823,529 | — | — | $37.62M | 1 | 2015-03-25 |
| PRTO | 10%+ Owner | 3,931 | $27.04 | $106.3K | $48.42M | 1 | 2014-10-27 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 825,603 | $38.22 | $31.55M | -$8.96M | 1 | 2014-10-15 |
| RIGL | 10%+ Owner | 78,770 | $38.50 | $3.03M | $36.40M | 1 | 2011-06-07 |
| NeuroMetrix, Inc. (NURO) Delisted | 10%+ Owner | 6 | $4.58 | $27 | -$2.98M | 3 | 2010-11-18 |
| MEDICINES CO /DE (MDCO) Delisted | 10%+ Owner | 2,416,432 | — | — | $45.35M | 2 | 2010-09-13 |
| SALIX PHARMACEUTICALS LTD (SLXP) Delisted | 10%+ Owner | 2,011,714 | — | — | -$50.33M | 3 | 2009-09-10 |
| NITROMED INC (NTMD) Delisted | 10%+ Owner | 1,936,622 | — | — | $1.50M | 3 | 2008-07-30 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | — | $15.50 | — | $0 | 1 | 2007-11-01 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | 10%+ Owner | 1,286,209 | — | — | -$315.4K | 1 | 2007-10-26 |
| THIRD WAVE TECHNOLOGIES INC /WI (TWTI) Delisted | 10%+ Owner | 1,308,529 | — | — | -$8.93M | 1 | 2007-05-22 |
Recent Filings
54 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-24 | NUVL | Sell (S) | −16,000,000 | -$1.56B | EDGAR |
| 2022-12-21 | Oncorus, Inc. (ONCR) Delisted | Sell (S) | −1,026,064 | -$301.0K | EDGAR |
| 2022-11-07 | NUVL | Buy (P) | +5,200,000 | $174.20M | EDGAR |
| 2021-10-28 | XLO | Mixed | +11,439,720 | $62.00M | EDGAR |
| 2021-08-03 | DA32 Life Science Tech Acquisition Corp. (DALS) Delisted | Mixed | +9,000,000 | $90.00M | EDGAR |
| 2021-06-10 | CareMax, Inc. (CMAXW) Delisted | Mixed | +53,675,000 | $400.00M | EDGAR |
| 2021-02-09 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Mixed | +9,528,132 | $45.22M | EDGAR |
| 2020-07-28 | ANNX | Mixed | +9,706,968 | $71.40M | EDGAR |
| 2020-07-22 | CareMax, Inc. (DFHTU) Delisted | Other (J) | +13,440,000 | $134.40M | EDGAR |
| 2020-02-10 | SDGR | Mixed | +9,577,002 | $25.50M | EDGAR |
Showing 1–10 of 54
Page 1 of 6
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.